Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar;62(3):853-864.
doi: 10.1007/s11517-023-02971-3. Epub 2023 Dec 7.

Magnetic resonance imaging and deoxyribonucleic acid methylation-based radiogenomic models for survival risk stratification of glioblastoma

Wentao Zhang #  1 , Zikang Yan #  2 , Jian Peng  3 , Shan Zhao  1 , Longke Ran  2 , Haoyang Yin  4 , Dong Zhong  4 , Junjun Yang  5 , Junyong Ye  6 , Shengsheng Xu  7
Affiliations

Magnetic resonance imaging and deoxyribonucleic acid methylation-based radiogenomic models for survival risk stratification of glioblastoma

Wentao Zhang et al. Med Biol Eng Comput. 2024 Mar.

Abstract

Glioblastoma multiforme (GBM) is one of the deadliest tumours. This study aimed to construct radiogenomic prognostic models of glioblastoma overall survival (OS) based on magnetic resonance imaging (MRI) Gd-T1WI images and deoxyribonucleic acid (DNA) methylation-seq and to understand the related biological pathways. The ResNet3D-18 model was used to extract radiomic features, and Lasso-Cox regression analysis was utilized to establish the prognostic models. A nomogram was constructed by combining the radiogenomic features and clinicopathological variables. The DeLong test was performed to compare the area under the curve (AUC) of the models. We screened differentially expressed genes (DEGs) with original ribonucleic acid (RNA)-seq in risk stratification and used Gene Ontology (GO) and Kyoto Encyclopaedia of Genes and Genomes (KEGG) annotations for functional enrichment analysis. For the 1-year OS models, the AUCs of the radiogenomic set, methylation set and deep learning set in the training cohort were 0.864, 0.804 and 0.787, and those in the validation cohort were 0.835, 0.768 and 0.651, respectively. The AUCs of the 0.5-, 1- and 2-year nomograms in the training cohort were 0.943, 0.861 and 0.871, and those in the validation cohort were 0.864, 0.885 and 0.805, respectively. A total of 245 DEGs were screened; functional enrichment analysis showed that these DEGs were associated with cell immunity. The survival risk-stratifying radiogenomic models for glioblastoma OS had high predictability and were associated with biological pathways related to cell immunity.

Keywords: Biological pathways; Glioblastoma; MRI; Prognosis prediction model; Radiogenomics.

PubMed Disclaimer

References

    1. Beig N, Bera K, Prasanna P, Antunes J, Correa R, Singh S et al (2020) Radiogenomic-based survival risk stratification of tumor habitat on Gd-T1w MRI is associated with biological processes in glioblastoma. Clin Cancer Res 26(8):1866–1876. https://doi.org/10.1158/1078-0432.CCR-19-2556 - DOI - PubMed - PMC
    1. Zhang X, Lu H, Tian Q, Feng N, Yin L, Xu X et al (2019) A radiomics nomogram based on multiparametric MRI might stratify glioblastoma patients according to survival. Eur Radiol 29(10):5528–5538. https://doi.org/10.1007/s00330-019-06069-z - DOI - PubMed
    1. X. Jia, Y. Zhai, D. Song, Y. Wang, S. Wei, F. Yang, et al. (2022) A multiparametric MRI-based radiomics nomogram for preoperative prediction of survival stratification in glioblastoma patients with standard treatment. Frontiers in Oncology 12. https://doi.org/10.3389/fonc.2022.758622
    1. J. Lao, Y. Chen, Z.-C. Li, Q. Li, J. Zhang, J. Liu, et al. (2017) A deep learning-based radiomics model for prediction of survival in glioblastoma multiforme. Scientific Reports 7(1). https://doi.org/10.1038/s41598-017-10649-8
    1. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D et al (2021) The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 23(8):1231–1251. https://doi.org/10.1093/neuonc/noab106 - DOI - PubMed - PMC

LinkOut - more resources